{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:23:53Z","timestamp":1794936233905,"version":"4.9.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1097\/ico.0000000000001024","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T13:35:35Z","timestamp":1474464935000},"page":"1611-1614","source":"Crossref","is-referenced-by-count":23,"title":["Combined Use of Rituximab and Intravenous Immunoglobulin for Severe Autoimmune Cicatricial Conjunctivitis\u2014An Interventional Case Series"],"prefix":"10.1097","volume":"35","author":[{"given":"Bernhard","family":"Steger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitha","family":"Madhusudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Stylianides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundas E.","family":"Maqsood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20210227","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"R2-22-20210227","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.1971.04000230009002","article-title":"Benign mucous membrane pemphigoid","volume":"104","author":"Hardy","year":"1971","journal-title":"Arch Dermatol"},{"key":"R3-22-20210227","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"key":"R4-22-20210227","first-page":"19","article-title":"A practical approach to treating autoimmune bullous disorders with systemic medications","volume":"2","author":"Han","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"R5-22-20210227","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000350818","article-title":"Linear immunoglobulin a bullous dermatosis: need for an agreement on diagnostic criteria","volume":"226","author":"Antiga","year":"2013","journal-title":"Dermatology"},{"key":"R6-22-20210227","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":"Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology"},{"key":"R7-22-20210227","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/14712598.2015.1046833","article-title":"Rituximab preserves vision in ocular mucous membrane pemphigoid","volume":"15","author":"R\u00fcbsam","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"R8-22-20210227","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"R9-22-20210227","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"R10-22-20210227","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R11-22-20210227","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/archopht.122.2.179","article-title":"A new method for measuring progression in patients with ocular cicatricial pemphigoid","volume":"122","author":"Rowsey","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R12-22-20210227","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","article-title":"Resolving the clinical acuity categories \u201chand motion\u201d and \u201ccounting fingers\u201d using the Freiburg Visual Acuity Test (FrACT)","volume":"247","author":"Lange","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R13-22-20210227","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bjo.80.4.292","article-title":"Progression of disease in ocular cicatricial pemphigoid","volume":"80","author":"Elder","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"R14-22-20210227","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1067\/mjd.2001.119100","article-title":"Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept","volume":"46","author":"Sacher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R15-22-20210227","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archderm.142.10.1268","article-title":"Successful treatment of mucous membrane pemphigoid with infliximab","volume":"142","author":"Heffernan","year":"2006","journal-title":"Arch Dermatol"},{"key":"R16-22-20210227","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"R17-22-20210227","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"R18-22-20210227","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1191\/0961203305lu2138oa","article-title":"Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases","volume":"14","author":"Chambers","year":"2005","journal-title":"Lupus"},{"key":"R19-22-20210227","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bjo.2007.129510","article-title":"The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement","volume":"93","author":"Ross","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R20-22-20210227","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","article-title":"Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up","volume":"111","author":"Sami","year":"2004","journal-title":"Ophthalmology"},{"key":"R21-22-20210227","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/S0161-6420(99)90496-7","article-title":"Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study","volume":"106","author":"Foster","year":"1999","journal-title":"Ophthalmology"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000001024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T21:16:55Z","timestamp":1620940615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201612000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000001024","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}